Screener
CytomX Therapeutics CTMX Interest Income
Interest Income at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.
The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337950
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| General and administrative | 7,601 | 6,622 | 18,294 | 16,050 |
| Total operating expenses | 25,199 | 19,944 | 55,130 | 48,239 |
| Income (loss) from operations | (23,781) | (1,286) | (43,453) | 21,336 |
| Interest income | 3,157 | 1,178 | 4,647 | 2,133 |
| Other income | 18 | 17 | 11 | 28 |
| Income (loss) before income taxes | (20,606) | (91) | (38,795) | 23,497 |
| Provision for income taxes | 60 | 63 | 119 | 126 |
| Net income (loss) attributable to common stockholders | (20,666) | (154) | (38,914) | 23,371 |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is CytomX Therapeutics's interest income?
- CytomX Therapeutics (CTMX) reported interest income of $3.16M in Q2 2026.
- How has CytomX Therapeutics's interest income changed year-over-year?
- CytomX Therapeutics's interest income increased by 168.0% year-over-year, from $1.18M to $3.16M.
- What is the long-term trend for CytomX Therapeutics's interest income?
- Over 4 years (2021 to 2025), CytomX Therapeutics's interest income has grown at a 112.6% compound annual growth rate (CAGR), from $255K to $5.21M.
- What does interest income mean?
- Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.
Ask your AI about CytomX Therapeutics's interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude